PROQR THERAPEUTICS EO-04 Capital Reinvestment Ratio

Latest as of December 2023: 0.06x

PROQR THERAPEUTICS EO-04 capital reinvestment ratio. PROQR THERAPEUTICS EO-04 (0PQ) has a Capital Reinvestment Ratio of 0.06x as of December 2023, meaning it reinvests 0% of its operating cash flow (€21.55 Million) in capital expenditures (€1.37 Million). Check how aggressively does PROQR THERAPEUTICS EO-04 reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.06x
Capex / Operating Cash Flow

Operating Cash Flow

€21.55 Million
EUR

Capital Expenditures

€1.37 Million
EUR

Data as of

Dec 2023
Most recent filing

Capital Reinvestment Ratio of PROQR THERAPEUTICS EO-04 (2023–2023)

Capital reinvestment ratio of PROQR THERAPEUTICS EO-04 from 2023 to 2023. This chart tracks PROQR THERAPEUTICS EO-04's Capital Reinvestment Ratio across 1 annual periods. Also explore 0PQ net asset momentum to track the company's year-over-year net asset growth rate.

PROQR THERAPEUTICS EO-04 Capital Reinvestment Ratio by Year (2023–2023)

PROQR THERAPEUTICS EO-04 capital reinvestment ratio by year from 2023 to 2023. For the full cash flow conversion analysis, see PROQR THERAPEUTICS EO-04 operating cash flow efficiency.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2023 0.06x €21.55 Million €1.37 Million —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow